2020
Lipid Lowering Treatment Patterns and Risk of Subsequent Cardiovascular Outcomes Among Patients Initially Rejected for pcsk9 Inhibitor Therapy
Desai N, Rane P, Nunna S, Chen C, Exter J, Habib M, Zhou Z, Wade R. Lipid Lowering Treatment Patterns and Risk of Subsequent Cardiovascular Outcomes Among Patients Initially Rejected for pcsk9 Inhibitor Therapy. Journal Of Clinical Lipidology 2020, 14: 599-600. DOI: 10.1016/j.jacl.2020.05.086.Peer-Reviewed Original Research
2019
Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients
Desai N, Rowan C, Alvarez P, Fogli J, Toto R. Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients. Journal Of Drug Assessment 2019, 8: 2-2. PMCID: PMC6764378, DOI: 10.1080/21556660.2019.1658287.Peer-Reviewed Original ResearchContinuous exposureRenin angiotensin aldosterone system inhibitor therapyAldosterone system inhibitor therapyDevelopment of hyperkalemiaCornerstone of therapyRetrospective cohort studyOptum Clinformatics DataMartMEq/LNational Health InsuranceBinder therapyHK cohortHyperkalemia treatmentPotassium bindersRAASi therapyIndex dateCohort studyInhibitor therapyContinuation ratesMean ageDiagnosis codesITT groupCardiovascular diseaseClinformatics DataMartMedicare patientsPatiromer